Search Results - "Price, Allyson"

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax by Siddiqui, Maria Tariq, Price, Allyson, Ferrajoli, Alessandra, Borthakur, Gautam

“…B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype…”
Get full text

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations by Daver, Naval, Price, Allyson, Benton, Christopher B., Patel, Keyur, Zhang, Weiguo, Konopleva, Marina, Pemmaraju, Naveen, Takahashi, Koichi, Andreeff, Michael, Borthakur, Gautam

“…The prognostics implications of patients with acute myeloid leukemia harboring non-canonical FLT3 is unknown. The use of tyrosine kinase inhibitors in this…”
Get full text

Appendix by Nix, Nancy M., Price, Allyson

Get full text

Biomarker Jeopardy by Kurtin, Sandra E, Henglefelt, Alyssa, Price, Allyson

“…The popular Biomarker Jeopardy session returned this year at JADPRO Live 2020. Sandra E. Kurtin, PhD, ANP-C, AOCN®, led the session, and was joined by Alyssa…”
Get full text

The Advanced Practitioner's Role in Treating Patients With Hematologic Malignancies: Highlights From SOHO 2020 by Price, Allyson

“…​Welcome to highlights from the eighth annual meeting of the Society of Hematologic Oncology (SOHO). The virtual conference took place from September 9 through…”
Get full text

Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation by Ghorab, Ahmad, Patel, Keyur, Cortes, Jorge E., Chihara, Dai, Price, Allyson, Kadia, Tapan M., Ravandi, Farhad, Pemmaraju, Naveen, Daver, Naval Guastad, Dinardo, Courtney Denton, Kantarjian, Hagop M., Borthakur, Gautam

“…Abstract only…”
Get full text

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia by Abou Dalle, Iman, Ghorab, Ahmad, Patel, Keyur, Wang, Xuemei, Hwang, Hyunsoo, Cortes, Jorge, Issa, Ghayas C., Yalniz, Fevzi, Sasaki, Koji, Chihara, Dai, Price, Allyson, Kadia, Tapan, Pemmaraju, Naveen, Daver, Naval, DiNardo, Courtney, Ravandi, Farhad, Kantarjian, Hagop M., Borthakur, Gautam

“…FLT3 -ITD mutations in newly diagnosed acute myeloid leukemia (AML) are associated with worse overall survival (OS). FLT3 -ITD diversity can further influence…”
Get full text

Acute Myeloid Leukemia: An Ever-Changing Disease by M. Nix, PharmD, BCPS, BCOP, Nancy, Price, MPAS, PA-C, Allyson

“…Acute myeloid leukemia is the most common form of acute leukemia in adults. In recent years, there has been robust characterization of molecular targets for…”
Get full text

Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia by Nix, Nancy M, Price, Allyson

“…Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the…”
Get full text

The Role of the Advanced Practitioner in Enhancing Outcomes by Nix, Nancy M, Price, Allyson

“…Advanced practitioners (nurse practitioners, physician assistants, pharmacists, and other health-care providers) have become increasingly integral members of…”
Get full text

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax by Siddiqui, Maria Tariq, Price, Allyson, Ferrajoli, Alessandra, Borthakur, Gautam

Get full text

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations by Daver, Naval, Price, Allyson, Benton, Christopher B, Patel, Keyur, Zhang, Weiguo, Konopleva, Marina, Pemmaraju, Naveen, Takahashi, Koichi, Andreeff, Michael, Borthakur, Gautam

Get full text